-

DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that Rick Pauls, President and CEO, will participate in the Jefferies Global Healthcare Conference in London, taking place November 17-20, 2025.

Mr. Pauls will deliver a corporate presentation and participate in one-on-one investor meetings during the conference.

Details

Jefferies Global Healthcare Conference in London
Time below is listed in Greenwich Mean Time (GMT)
Corporate Presentation:
Date: Thursday, November 20, 2025
Time: 10:00-10:25 AM

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein to be clinically studied in the United States. Human-derived KLK1 is an established therapeutic modality in China for the treatment of acute ischemic stroke and other vascular diseases,. For more information visit the Company’s website at www.diamedica.com.

Contacts

Corporate Contact:
Scott Kellen, Chief Financial Officer
(763) 496-5118 | skellen@diamedica.com

Investor Contact:
Mike Moyer, Managing Director, LifeSci Advisors
mmoyer@lifesciadvisors.com

Media Contact:
Madelin Hawtin, LifeSci Communications
mhawtin@lifescicomms.com

DiaMedica Therapeutics Inc.

NASDAQ:DMAC

Release Versions

Contacts

Corporate Contact:
Scott Kellen, Chief Financial Officer
(763) 496-5118 | skellen@diamedica.com

Investor Contact:
Mike Moyer, Managing Director, LifeSci Advisors
mmoyer@lifesciadvisors.com

Media Contact:
Madelin Hawtin, LifeSci Communications
mhawtin@lifescicomms.com

More News From DiaMedica Therapeutics Inc.

DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that its full-year 2025 financial results will be released after the markets close on Monday, March 30th. DiaMedica will host a live conference call on Tuesday, March 31st at 7:00 AM Central Time to provide a business update and discuss financial resu...

DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that it has received a No Objection Letter (NOL) from Health Canada for its Clinical Trial Application to evaluate DM199 in a Phase 2 trial in patients with early-onset preeclampsia (PE). This regulatory clearance enables DiaMedica to initiate its Pha...

DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that company management will participate in three upcoming investment bank conferences. Details TD Cowen 46th Annual Healthcare Conference Boston, Massachusetts  Fireside chat with Rick Pauls, CEO, and Julie Krop, M.D., Chief Medical Officer, on Monday, Mar...
Back to Newsroom